Editor-in-Chief
Hatice Kübra Elçioğlu
Vice Editors
Levent Kabasakal
Esra Tatar
Online ISSN
2630-6344
Publisher
Marmara University
Frequency
Bimonthly (Six issues / year)
Abbreviation
J.Res.Pharm.
Former Name
Marmara Pharmaceutical Journal
Marmara Pharmaceutical Journal
2016 , Vol 20 , Issue 3
Controlled Porosity Osmotic Tablet of Atenolol: In-Vitro and In-Vivo Evaluation
1Department of Pharmaceutics Y.B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus Rauza bagh Aurangabad-431001, India
DOI :
10.12991/mpj.20162040694
The aim of the present study was to design a controlled porosity
osmotic pump tablet of atenolol. The controlled porosity
osmotic pump tablet contains pore-forming water-soluble
additives in the coating membrane, which after coming in
contact with water, dissolve, resulting in an in situ formation
of a microporous structure. The dosage regimen of atenolol is
25-mg tablet 2 to 3 times a day. The plasma half-life ranges from
~6 to 7 hours. Hence, Atenolol was chosen as a model drug with
an aim to develop a controlled release system for a period of
12 hours. The effect of different formulation variables, namely,
ratio of drug to osmogent and level of pore former on the in vitro release was studied by applying a full 32 factorial design.
Cellulose acetate (CA) was used as a semipermeable membrane.
It was found that drug release was directly related to the
amount of osmogent and level of pore former. In-vivo study was
performed in rabbits and various parameters Cmax, tmax, AUC,
AUMC and MRT were calculated and compared with that of
marketed conventional tablet. The optimized formulation was
subjected to stability studies as per International Conference on
Harmonization (ICH) guidelines and formulation was stable
after a 3 month study.
Keywords :
Atenolol, Controlled Porosity Osmotic pump tablet, Antihypertensive , In vivo study